Paxlovid

  • Recently, US based pharma company Pfizer received United States Food and Drug Administration (USFDA) emergency use authorization for its COVID-19 antiviral treatment Paxlovid.
  • It is an antiviral COVID-19 treatment candidate - PF-07321332 - which is administered in combination with low dose HIV medicine ritonavir.
  • As compared to the placebo group, it showed a reduced risk of hospitalisation or death by 89 per cent, within three days of symptom onset; and 88 per cent, within five days of symptom onset.
  • Paxlovid can be administered to adults with COVID-19 who do not require supplemental oxygen and are at increased risk of progressing to severe ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy February 2022 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content

News Snippets